Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury

Clinical and Experimental Immunology

Volumn 165, Issue 2, 2011, Pages 278-284

  Tuinman, P R ^a   Gerards, M C ^a   Jongsma, G ^a   Vlaar, A P ^a   Boon, L ^b   Juffermans, N P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b BIOCEROS   (Netherlands)

Author keywords

Cardiac surgery; CD40 ligand; MHC 1 antibody; TRALI; Transfusion

Indexed keywords

CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CIGLITAZONE; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART SURGERY; HUMAN; LUNG FLUID; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSFUSION RELATED ACUTE LUNG INJURY;

ACUTE LUNG INJURY; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; BLOOD PLATELETS; BLOOD TRANSFUSION; BRONCHOALVEOLAR LAVAGE FLUID; CD40 LIGAND; CHEMOKINE CXCL2; CHEMOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, MHC CLASS I; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PLATELET ACTIVATION; THIAZOLIDINEDIONES;

EID: 79960073710     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04422.x     Document Type: Article

References (45)

1. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005; 19:2-31.
2. Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006; 34:S124-S131.
3. Silliman CC, Boshkov LK, Mehdizadehkashi Z etal. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101:454-62.
4. Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang 2011; 100:122-8.
5. Silliman CC, Paterson AJ, Dickey WO etal. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997; 37:719-26.
6. Silliman CC, Bjornsen AJ, Wyman TH etal. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003; 43:633-40.
7. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, Frenette PS. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 2009; 15:384-91.
8. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006; 116:1615-23.
9. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119:3450-61.
10. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92:1041-8.
11. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
12. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000; 97:6930-2.
13. Khan SY, Kelher MR, Heal JM etal. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 108:2455-62.
14. Roselli M, Mineo TC, Basili S etal. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004; 10:610-14.
15. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009; 21:293-300.
16. Novo S, Basili S, Tantillo R etal. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 2005; 36:673-5.
17. Aukrust P, Muller F, Ueland T etal. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100:614-20.
18. Wyman TH, Bjornsen AJ, Elzi DJ etal. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol 2002; 283:C1592-C1603.
19. Adawi A, Zhang Y, Baggs R, Finkelstein J, Phipps RP. Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. Am J Pathol 1998; 152:651-7.
20. Hashimoto N, Kawabe T, Imaizumi K etal. CD40 plays a crucial role in lipopolysaccharide-induced acute lung injury. Am J Respir Cell Mol Biol 2004; 30:808-15.
21. Adawi A, Zhang Y, Baggs R etal. Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol 1998; 89:222-30.
22. Kaufman J, Spinelli SL, Schultz E, Blumberg N, Phipps RP. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost 2007; 5:788-96.
23. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002; 105:2849-54.
24. Stegenga ME, Florquin S, de Vos AF, van der Poll T. The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice. Crit Care Med 2009; 37:614-18.
25. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104:1361-8.
26. Marx N, Imhof A, Froehlich J etal. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107:1954-7.
27. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 1993; 178:1567-75.
28. Stax AM, Gelderman KA, Kamerling SW, van der Geest R, Schlagwein N, van KC. Generation and characterization of a novel anti-rat CD40L antibody with inhibitory activities in vitro and in vivo. J Immunol Methods 2008; 335:46-52.
29. Vlaar AP, Wolthuis EK, Hofstra JJ etal. Mechanical ventilation aggravates transfusion-related acute lung injury induced by MHC-I class antibodies. Intens Care Med 2010; 36:879-87.
30. Vlaar AP, Hofstra JJ, Determann RM etal. The incidence, risk factors and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case control study. Blood 2011; 117:4218-25.
31. Toy P, Popovsky MA, Abraham E etal. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33:721-6.
32. Vlaar AP, Binnekade JM, Prins D etal. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med 2010; 38:771-8.
33. Henn V, Slupsky JR, Grafe M etal. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391:591-4.
34. Santilli F, Basili S, Ferroni P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007; 2:256-68.
35. Nierkens S, van HP, Bol M etal. Selective requirement for CD40-CD154 in drug-induced type 1 versus type 2 responses to trinitrophenyl-ovalbumin. J Immunol 2002; 168:3747-54.
36. Vlaar AP, Hofstra JJ, Kulik W etal. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model. Blood 2010; 116:1360-8.
37. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol 1996; 27 (Suppl. 1):S1-5.
38. Gillinov AM, Bator JM, Zehr KJ etal. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993; 56:847-53.
39. Blumberg N, Gettings KF, Turner C, Heal JM, Phipps RP. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006; 46:1813-21.
40. Dongari-Bagtzoglou AI, Thienel U, Yellin MJ. CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent. Inflamm Res 2003; 52:18-25.
41. Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 2000; 437:396-405.
42. Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41:997-1000.
43. Hebert PC, Fergusson D, Blajchman MA etal. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289:1941-9.
44. Vlaar AP, Hofstra JJ, Determann RM etal. Transfusion-related acute lung injury in cardiac surgery patients is hemerus characterized by systemic inflammation prior to onset of disease, followed by pulmonary activation of inflammation and coagulopathy. Transfusion 2010; 50 (Suppl 2):P4-020A.
45. Danese S, Katz JA, Saibeni S etal. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52:1435-41.